Clinical Trials Directory

Trials / Completed

CompletedNCT05480852

Clinical Performance of BIS-GMA Free Dental Resin Composite

Clinical Performance of BIS-GMA Free Dental Resin Composite as Posterior Restoration: a Randomized Clinical Trial

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
40 (actual)
Sponsor
Minia University · Academic / Other
Sex
All
Age
20 Years – 45 Years
Healthy volunteers
Accepted

Summary

Resin composites were introduced for restoring defective teeth commercially in the mid- 1960s as an alternative to acrylic resin and silicate cements. As one of the most significant contributions to dentistry, dental resin composites usually have three components as organic resin matrix, photo initiator system, and coupling agent treated inorganic fillers. At present, the most commonly used organic resin matrix for dental resin composites are based on di-methacrrylates such as 2.2- bis \[p-(2- hydroxy-3- methacryloxypropoxy) penylene\] propane (Bis-GMA), ethoxylated bisGMA, 1,6-bis(2-methacryloyoxy-ethoxycarbonyl-amino)-2,4,4tri-methyl-hexane (UDMA) and triethyleneglycoldimethacrylate (TEGDMA). The application of Bis-GMA has been doubted since it was reported to have estrogenic activity in a cell culture assay.Though later studies have showed that Bis-GMA does not hydrolyse into the estrogenic substance BPA, BPA has still been detected to be release out of several commercial Bis-GMA-based dental restorative materials. Although there is a lack of studies analysing the association between BPA exposure from dental materials and its adverse effects on human health, there is a need to develop newer BPA-free resin composites to minimize human exposure to this compound. Accordingly, the objective of this study was to evaluate the performance of BIS- GMA- free composite as a photopolymerizable posterior dental composite restoration.

Detailed description

Hypothesis: The null hypothesis is that there is no difference in using the new BIS- GMA- free composite. Aim of the study: This clinical trial was conducted to compare the clinical performance of the new BIS- GMA- free composite versus BIS-GMA- containing composite in the management of carious lesion in adult patients over 9 months. The two types of composites will be evaluated using USPHS criteria for: * Retention (R). * Contact (C). * Color match (CM). * Marginal adaptation (MA). * Marginal discoloration (MD). * Anatomic form (AF). * Secondary caries (SC). * Surface texture (ST). * Gingival inflammation (GI). * Post-operative sensitivity (POS). * Patient complaints (PC). * Patient satisfaction (PS). * The evaluation done by three calibrated operators. The study was conducted in Operative Dentistry Department, Faculty of Dentistry, Menia University. The researcher was bear ultimate responsibility for all activities associated with the conduct of a research project including recruitment of patients, explaining, and performing the procedures to them. \- Intervention: BIS- GMA- free composite material: Tooth preparation and restoration was carried out using magnifying loops. All cavities were restored using composite resin. cavities, including the dentin, were acid etched for 30 s, rinsed thoroughly for 15 s, bonded with universal adhesive and light cured for 10 s prior to placing the filling material. Restorations were light cured for 20 s, check the occlusion, finished with diamond burs and polished with Kenda hybrid composite pre- and super-polishers (Kenda, Vaduz, Liechtenstein). \- Comparator: BIS- GMA- containing composite material: The same methodology of the intervention BIS-GMA- free composite material If the patient showed any complications during our clinical trial toward either the intervention (BIS- GMA- free composite) or the comparator (BIS-GMA containing composite material), the trial will be stopped at once and all the needed management against any complications will be done.

Conditions

Interventions

TypeNameDescription
OTHERBis-GMA Free dental resin compositeRestorative Material

Timeline

Start date
2021-05-20
Primary completion
2022-06-15
Completion
2022-07-06
First posted
2022-07-29
Last updated
2022-07-29

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT05480852. Inclusion in this directory is not an endorsement.